RxDoctor Payments Data

Grant Lange, DO

Internal Medicine · Shelby Township, MINPI 1427051127

Payments from drug & device makers

$1,522in general payments, 2019–2025

Across 108 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$600
  • Amgen$149
  • Pfizer$147
  • Novo Nordisk$98
  • Lilly USA, LLC$90
  • Johnson & Johnson$81
  • plus $357 from 10 others

What the payments were for

  • Speaking & faculty fees$252%
  • Food & beverage$1,49798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,522 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$72,619
Medicare patients
209
Services billed
4,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$150,302
OzempicSemaglutide90$112,612
EliquisApixaban107$110,532
MounjaroTirzepatide59$70,388
XareltoRivaroxaban34$34,592
JanuviaSitagliptin Phosphate20$31,957
TradjentaLinagliptin21$29,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,119
Tresiba Flextouch U-100Insulin Degludec31$15,685
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$10,422
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$9,266
Atorvastatin Calcium610$8,519
ElmironPentosan Polysulfate Sodium11$7,127
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,536
SymbicortBudesonide/Formoterol Fumarate18$6,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$65$180,090122 claims
Novo NordiskOzempic$98$112,61290 claims
PfizerEliquis$147$110,532107 claims
Lilly USA, LLCMounjaro$90$70,38859 claims
Johnson & JohnsonXarelto$81$34,59234 claims
GSKTrelegy Ellipta, Anoro Ellipta$73$29,65441 claims
AstraZenecaSymbicort$14$6,30618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Shelby Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →